Stay in the know
Receive timely insights and briefings from HSF Kramer, tailored to keep you informed and ahead
Subscribe now
Herbert Smith Freehills Kramer (HSF Kramer) is pleased to be advising CSL on its recently announced proposed demerger of its Seqirus business (Seqirus) as a standalone ASX-listed entity by the end of Financial Year 2026.
Seqirus is one of the world’s largest influenza vaccine providers, dedicated to advancing public health through innovative vaccine solutions and pandemic preparedness.
The HSF Kramer team is led by partners Priscilla Bryans, Baden Furphy, Alexander Mackinnon, and Michael Ziegelaar, with partner Ryan Leslie advising on the tax aspects of the transaction.
Key contacts
Priscilla Bryans
Partner, Melbourne
Baden Furphy
Partner, Melbourne
Alexander Mackinnon
Partner, Melbourne
Michael Ziegelaar
Partner, Melbourne
Ryan Leslie
Partner, Melbourne
Media contact
For further information on this news article, please contact:
Gina Baldassarre
External Communications Manager
Sydney
More news
16 сентября 2026
Herbert Smith Freehills Kramer advises Zankore on US$3.1 billion financing for AI infrastructure
Leading global law firm Herbert Smith Freehills Kramer has advised Zankore on a US$3.1 billion senior term loan facility, one of Asia’s largest AI …
15 сентября 2026
Herbert Smith Freehills Kramer advises PBF Energy in $500 million offering of exchangeable senior notes
On September 14, 2026, Herbert Smith Freehills Kramer (HSF Kramer) client PBF Energy Inc. (NYSE:PBF) announced that its indirect subsidiary, PBF Holding …
11 сентября 2026
Nine Herbert Smith Freehills Kramer attorneys named to the 2027 Lawdragon 500 list of Leading Litigators in America
Lawdragon 500 has recognized nine Herbert Smith Freehills Kramer (HSF Kramer) attorneys in its 2027 Leading Litigators in America guide. This guide …